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Abstract A receptor for advanced glycation end products
(RAGE) and its ligand high mobility group box 1
(HMGB1) protein has been linked to several chronic dis-
eases, and acts as a trigger for inflammation signaling.
Here, we study RAGE and HMGB1 expression in chronic,
recalcitrant rhinosinusitis with nasal polyps (CRSwNP) to
determine its potential clinical significance, i.e., disease
recurrence and severity. RAGE and HMGB1 expression in
CRSwNP was evaluated by immunohistochemistry in
epithelial cells of fresh sinonasal mucosa samples obtained
from the patients diagnosed with recalcitrant CRSwNP
(n = 25) and normal control mucosa (NC) (n = 26).
RAGE and HMGB1 expression levels in tissues were
correlated with disease severity assessed by nasal endos-
copy, CT scan, number of previous sinus surgeries, allergy
status and nasosinusal microbiology. RAGE and HMGB1
were moderately or strongly expressed in CRSwNP tissue.
No or weak RAGE expression was found in NC. HMGB1
was equally strongly expressed in NC. We observed a
strong correlation between RAGE and disease severity,
recurrence, undergone operations, asthma and aspirin
exacerbated respiratory disease (AERD). Elevated RAGE
expression is associated with increased disease severity, as
well as allergy and AERD in patients with recalcitrant
CRSwNP. It is possible that the explanation for recurrent
CRSwNP pathogenesis might be related to RAGE
overexpression with subsequent sinus mucosa hyperpro-
liferation, necessitating several operations.
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Abbreviations
HMGB1 High mobility group box 1
RAGE Receptor for advanced glycation end products
CRSwNP Chronic rhinosinusitis with nasal polyps
NPs Nasal polyps
AERD Aspirin exacerbated respiratory disease
H?E Hematoxylin-eosin
DAMPs Damage-associated molecular patterns
EPOS European position paper on rhinosinusitis
Introduction
Recent studies suggest that the receptor for advanced gly-
cation end products (RAGE) has been implicated in
initiating and perpetuating inflammatory responses. Due to
an enhanced level of RAGE ligands in chronic disorders,
this receptor is hypothesized to have a causative effect in a
range of inflammatory diseases (Bassi et al. 2008; Singh
et al. 2014). RAGE is a multiligand receptor and a member
of the immunoglobulin superfamily of cell surface mole-
cules which is found on smooth muscle cells, macrophages,
endothelial cells and astrocytes. Its name comes from its
ability to bind advanced glycation end products (AGE)
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(Singh et al. 2014). Most characterized RAGE ligands are
either released during cell stress (S100 proteins, high
mobility group box 1 (HMGB1) protein and nucleic acids),
or generated during prolonged hyperglycemia and inflam-
mation (AGE, amyloid) (Sims et al. 2010). Some authors
characterize RAGE as a cell surface receptor that influ-
ences the concentration threshold at which DNA activates
inflammatory responses in vitro and in vivo (Sirois et al.
2013). RAGE binds directly to DNA and RNA, and pro-
motes their uptake into cells, lowering the immune
recognition threshold for activation of Toll-like receptor 9
(TLR9), the principal DNA-recognizing transmembrane
signaling receptor. A higher level of nucleic acid concen-
tration, such as during infections or in situations of
increased cell damage, can trigger signaling via RAGEs
and their downstream inflammatory effects. RAGE can
thereby sensitize cells to extracellular nucleic acids.
Recent studies suggest that the interaction between
RAGE and its ligand HMGB1 has been linked to several
chronic diseases (Yang et al. 2013). HMGB1-RAGE
interaction provides an extracellular trigger for inflamma-
tory cell proliferation, migration and survival (Erlandsson
Harris and Andersson 2004; Raucci et al. 2007; Sims et al.
2010; Ulloa and Messmer 2006; Yang et al. 2013).
HMBG1 also has the capacity to bind other molecules,
such as lipopolysaccharides and to induce maturation of
dendritic cells via activation of TLR4 (Youn et al. 2008).
The pathogenesis of persistent inflammation is hypothe-
sized to include ligand binding, upon which RAGE signals
activate the nuclear factor (NF)-jB. NF-jB controls sev-
eral genes involved in inflammation. RAGE itself is
upregulated by NF-jB. These interactions trigger the
activation of key signaling pathways involved in the reg-
ulation of innate and adaptive immunity (Andersson and
Tracey 2004b).
Notwithstanding this evidence, and the fact that RAGE
and HMGB1 have been proposed as a novel therapeutic
target for infectious and inflammatory disorders (Anders-
son and Erlandsson-Harris 2004; Andersson and Tracey
2004a, 2011; Mantell et al. 2006; Schierbeck et al. 2011),
no data have been published concerning the expression and
function of RAGE and HMGB1 in recalcitrant nasal
polyposis.
Nasal polyps (NPs) are a very common inflammatory
disease classified as a subtype of chronic sinusitis, chronic
rhinosinusitis with nasal polyps (CRSwNP) (Fokkens et al.
2012). The prevalence of NPs is increased in patients
diagnosed with cystic fibrosis, asthma, non-steroidal anti-
inflammatory drug intolerance aspirin exacerbated respi-
ratory disease (AERD), Churg-Strauss syndrome, or
sarcoidosis. Although the source of inflammation may be
variable, researchers theorize that these inciting events lead
to disruption of the epithelial lining and initiate a resultant
inflammatory cascade (Fokkens et al. 2012). If this
inflammation does not subside in its normal timely fashion,
stromal edema consolidates and may result in polyp for-
mation (Norlander et al. 1996).
Because the pathway that leads to the formation of NPs
has not been completely elucidated, effective long-term
treatments remain difficult to pinpoint. Those patients who
showed recurrence of NPs despite surgery and a postop-
erative regimen including topical steroids are classified as
recalcitrant CRSwNPs. Patients without endoscopic evi-
dence of polyps at least 6 months after surgery are
classified as responsive CRSwNPs (Reh et al. 2010). Novel
therapeutic targets are, therefore, needed for developing
new medical therapies for recalcitrant CRSwNP. We
hypothesize that RAGE and its ligand, HMGB1, could play
a critical role in NPs. RAGE-mediated augmentation of
inflammation can be deregulated in immune pathologies.
RAGE, therefore, represents an attractive target for phar-
macological intervention. The present study investigates
the expression of RAGE and HMGB1 in epithelial cells of
sinonasal mucosa (SM) obtained from the patients with
recalcitrant CRSwNP vs. normal controls (NC) and dis-
cusses the role of RAGE and HMGB1 in the pathogenesis
of recalcitrant rhinosinusitis and disease severity.
Materials and Methods
Tissues
Fresh sinus mucosa samples from the patients diagnosed
with CRSwNP were obtained during surgery from the os-
tiomeatal complex and stored. Patients were subsequently
classified as either treatment responsive or treatment
recalcitrant, based on the long-term outcomes of medical
and surgical therapy. Patients without endoscopic evidence
of NPs at least 6 months after surgery were classified as
responsive CRSwNPs and excluded from the study. Those
patients who showed recurrence of NPs despite surgery and
a postoperative regimen including topical steroids were
classified as recalcitrant CRSwNPs (n = 25) and included
in the study. The CRSwNPs patients included 13 males and
12 females (median age: 47 years; range 24–77 years). The
mucosa samples were obtained from ostiomeatal complex
region: the uncinate process or lateral surface of middle
nasal concha if the patient had had surgery before. As NC,
patients with nasal structural deformities without clinical
and radiological evidence of chronic rhinosinusitis were
included (n = 26). NC samples included non-inflammatory
changed normal mucosa from the uncinate process of the
ostiomeatal complex region. The group of NC comprised
18 men and 8 women (median age: 40 years; range
16–69 years). Table 1 summarizes characteristics of the
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patients included in this study. The study was in accor-
dance with the ethical standards of the Local Ethics
Committees of Warsaw Medical University in Poland (No.
KB 103/2012) and with the Helsinki Declaration. All par-
ticipants signed an informed consent.
Disease Severity Measure
The classification of disease severity was performed using
endoscopic appearance scores—Lund polyp staging system
(Lund and Kennedy 1995) and CT scan graded by Lund-
Mackay scoring system (Fokkens et al. 2012; Lund and
Kennedy 1997). We also recorded the number of sinus
surgeries that had been performed before our surgery as a
reflection of the recalcitrance of the NPs.
Disease Etiology
Allergy Status
In looking for etiology of NPs, allergy status was assessed
based on a medical interview, a skin prick test and a total
IgE level in patients’ blood samples. AERD and asthma
were diagnosed based on spirometry and medical anam-
nesis, according to the global initiative for asthma (GINA)
criteria.
Microbiology
To determine the nasosinusal microbiology, regardless of
the presence of mucopus, middle meatus cultures were
obtained under endoscopic control followed by agar
culture.
Cytology
To determine the population of inflammatory cells in the
nasal cavity, cytology was taken endoscopically under the
middle turbinate. The cells were smeared on glass slides,
fixed with alcohol, stained with hematoxylin-eosin (H?E)
and evaluated under a light microscope (Tarchalska-
Krynska et al. 1993).
Immunohistochemistry
The surgically removed tissues were fixed in 10 % form-
aldehyde and sections stained with H?E were prepared and
evaluated by light microscopy. The following primary
antibodies were used for immunostaining of tissue sections:
rabbit polyclonal anti-human HMGB1 (Abcam, Cam-
bridge, UK), rabbit polyclonal anti-human RAGE
(LifeSpan Bioscience Inc., Seattle, WA, USA) and isotype
control IgG (Dako, Gdynia, Poland). Paraffin sections of
SM tissues and control-SM were stained as previously
described (Szczepanski et al. 2009). After standard depar-
affinization, the EnVision?System (Dako) was used for
staining according to the manufacturer’s instructions. In
short, after an overnight incubation with the antibodies,
sections were first incubated with labeled polymer-horse-
radish peroxidase anti-rabbit antibody and then with 3,30-
diaminobenzidine. To eliminate non-specific binding of the
secondary antibody, tissue sections were incubated with a
serum-free protein blocker before adding the primary
antibodies. Sections were counterstained with Meyer’s
hematoxylin and mounted in resin. Slides were evaluated in
a light microscope (magnification: 2009 or 4009). For
digital image analysis, the software AnalySIS^B was used.
All stained sections were analyzed and scored by two
independent investigators (M. J. S. and K. D.) to avoid
bias, and the two scores were averaged and recorded. The
sections were scored according to the percentage of rhi-
nosinusitis tissue staining positively for HMGB1 or RAGE
(\25 % = 0; 25–75 % = 1; and[75 % = 2). The level of
staining intensity was recorded as 0: none, 1: weak, 2:
moderate, or 3: strong. For the better understanding of
RAGE and HMGB1 expression, intensity and positivity
Table 1 Clinicopathological characteristics of NC patients and














Allergy 2 10 p = 0.009
Asthma 0 8 p = 0.004














25 % 45 %
The patients included in the study received no oral steroids 2 months
before surgery
AERD aspirin exacerbated respiratory disease
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staining were combined and shown as a RAGE/HMGB1
ratio. As positive control tissues for HMGB1 and RAGE
staining, the intestine and kidney were used, respectively.
Statistical Analysis
Data were summarized by descriptive statistics. Fisher’s
exact tests were used to determine if there was a difference
in HMGB1 and RAGE expression among tissue types.
Adjustments to p values were made using the Bonferroni
step-down procedure. The ANOVA Kruskala-Wallisa test




In 25 cytograms taken from NPs, neutrophils predomi-
nance was found in 5 samples and eosinophils
predominance in 20 samples. NC group showed a normal
nasal cytology, characterized by the presence of many
ciliated cells and muciparous cells, at the typical ratio
4–5:1. The results are consistent with the previously pub-
lished data (Gelardi et al. 2009; Miszke and Sanokowska
1995). However, cytological data did not correlate with
HMGB1 and RAGE expression (Fig. 1a).
HMGB1 Expression in Tissue Sections
HMGB1 was detected in all NC and CRSwNPs tissues.
HMGB1 was localized in the nuclei and cytoplasm and in
all cases staining intensity was evaluated as moderate or
strong (Fig. 1b). We did not find statistically significant
differences between NC vs. CRSwNPs in terms of HMGB1
expression in epithelial cells of SM (p[ 0.05; Fig. 1c). No
correlation was found between HMGB1 expression and
disease severity performed by nasal endoscopy examina-
tion, CT scan or number of prior surgeries. Furthermore,
we did not find any significant differences in HMGB1
expression with respect to allergic or microbiological
status.
RAGE Expression in Tissue Sections
RAGE was detected in the cytoplasm of all patients with
CRSwNPs and its staining intensity ranged from weak to
strong. In contrast, RAGE was observed in the cytoplasm
of only 40 % of NC patients, with the intensity of RAGE
staining ranging from negative to weak (Fig. 1b). We
found a significant difference in terms of RAGE expression
in CRSwNPs vs. NC (p\ 0.0000001; Fig. 1d).
RAGE Expression Correlates with Disease Severity
In the CRSwNPs cohort, we observed significant correla-
tions between RAGE ratio and severity of CT scan findings
as graded by the Lund-Mackay scoring system. RAGE
expression was stronger in patients with a higher CT score
reflecting more extensive inflammatory changes in sinuses
(p\ 0.00001; Fig. 2a). We also observed significant cor-
relation between RAGE ratio and the nasal polyp size
noticed on endoscopy examination (p\ 0.00013; Fig. 2b).
RAGE staining also correlated with the number of prior
sinus surgeries in the CRSwNPs group (p = 0.04; Fig. 2c).
RAGE Expression Correlates with Disease Etiology
We observed significantly stronger RAGE expression in
sinus mucosa of patients who suffered from asthma and
AERD compared to other patients with negative anamnesis
(Fig. 3). We did not observe any correlation between
RAGE expression and allergy status or IgE titer. In the
study, the microbiological status of nasal cavity and any
specific microbe presence did not correlate with RAGE
expression (p[ 0.05).
Discussion
A complex set of innate and adaptive immune pathways are
active at the mucosal surface both constitutively and in
response to specific antigens. Over activity or deregulation
of the mucosal immune mechanism could lead to damaging
persistent inflammation. To our knowledge, expression and
function of RAGE in mucosal immunity of the sinonasal
tract has not been explored. Currently, pathogenesis of
CRSwNP is associated with aberrant innate or adaptive
immune responses that may initially result from inappro-
priate expression of RAGE and HMGB1 protein or/and
responses to its signaling pathway. To address this
hypothesis we sought to understand the role of RAGE in
recalcitrant CRSwNPs pathogenesis and the manner in
which RAGE interacts with its ligand HMGB1 in the SM.
Here, we assess for the first time the expression level of
RAGE in recalcitrant CRSwNPs and its target HMGB1
protein. In our study, HMGB1 was detected in all NC and
CRSwNP tissues. HMGB1 was localized in the nuclei and
cytoplasm, and in all cases staining intensity was evaluated
as moderate or strong (Fig. 1b); no significant differences
were observed between NC and CRSwNP patients
(Fig. 1c). We investigated expression of HMGB1 in the
whole tissue of NPs and mucosa, including the epithelial
cells and the stroma of SM obtained from patients with
CRSwNP vs. epithelial cells of nasal mucosa of NC.
Available literature data indicated HMGB1 expression
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mainly in the inflammatory infiltrates (or polyps tissue) and
not only in epithelial cells (Bellussi et al. 2012). In these
studies, HMGB1 expression levels correlated significantly
with eosinophilic infiltration and was higher in patients
with large inflammatory cells infiltration in eosinophilic
CRSwNP than in the controls. However, no significant
differences in the HMGB1 protein level as well as the
messenger RNA of HMGB1 were found between non-
eosinophilic CRSwNP and controls (Chen et al. 2014). This
observation is consistent with our findings.
RAGE was identified in the cytoplasm of CRSwNP
patients more commonly than in NC patients, with con-
sistently greater staining intensity in the positively
staining subjects (Fig. 1b). Van Crombruggen et al.
(2012) reported that RAGE is highly expressed in the
human upper airways under normal physiology. In their
CRSwNP patients, tissue levels of both soluble RAGE
(sRAGE) and membrane-bound RAGE (mRAGE) were
significantly lower versus the levels measured in control
tissue. However, the relative levels in gene expression for
mRAGE showed no difference between the CRSwNP
patient and NC, while endogenous secretory RAGE was
modestly but significantly higher in CRSwNP vs. control
tissue. Nevertheless, some authors consider HMGB1
expression or RAGE separately and do not report
HMGB1 and RAGE co-expression in their patients
(Bellussi et al. 2013; Chen et al. 2013). For other authors,
judging from the RAGE-DNA complex structure, it is
clear that HMGB1 is not essential for the RAGE-DNA
binding event, as DNA can bind to RAGE in the absence
of HMGB1 (Sirois et al. 2013). This observation could be
responsible for differences between RAGE and HMGB1
expression noticed in our study.
bFig. 1 HMGB1 and RAGE expression in NC and in recalcitrant
chronic rhinosinusitis with nasal polyps (CRSwNP) tissues. a1 H?E
staining of NC mucosa (9100); a2 H?E staining of NC cytology
taken under middle turbinate (9400); a3 H?E staining of CRSwNP
mucosa (9100); a4 H?E staining of CRSwNP cytology taken under
middle turbinate (9400); b1 HMGB1 expression in the intestine
(positive control; 9200); b2 HMGB1 expression in NC tissue
(9200); b3 HMGB1 expression in CRSwNP tissue (9200); B4
isotype control staining (9200); b5 RAGE expression in the kidney
(positive control; 9200); b6 RAGE expression in NC tissue (9200);
b7 RAGE expression in CRSwNP tissue (9200); b8 isotype negative
control staining in CRSwNP tissue (9200). The sections were scored
according to the percentage of rhinosinusitis tissue staining (positiv-
ity) (\25 % = 0; 25–75 % = 1; and [75 % = 2). The level of
staining intensity was recorded as 0: none, 1: weak, 2: moderate, or 3:
strong; as described in ‘‘Materials and Methods’’). c Intensive
HMGB1 immuno reactivity in both the epithelium lining nasal polyps
(marked with arrows) and the stroma of nasal polyps (marked with
stars). Representative pictures are shown. d Statistical analysis of
RAGE expression in tissues. A p value of less than 0.05 was
considered to be significant
Fig. 2 RAGE expression in correlation with disease severity.
a RAGE ratio vs. CT scoring in both investigated groups; b RAGE
ratio vs. polyp size; c RAGE ratio vs. number of previous surgery;
p values were used to evaluate differences between CRSwNP patients
and NC according to Bonferroni step-down procedure
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In our research, we found correlations between RAGE
expression and disease severity including CT score, NP size
and number of previous surgeries (Fig. 2). Based on these
observations, we took under consideration the RAGE role in
recalcitrant CRSwNPor recurrence after primary surgery.
This correlation confirms a deregulation of the normal
RAGE function as a consequence of the inflammatory and
remodeling mechanisms involved in NP and furthermore
suggests the implication of other factors in this process.
Deregulation of RAGE and HMGB1 in the immune barrier
function potentially compromises host defense and makes
the sinus mucosa more susceptible to antigenic exposition,
leading to chronic inflammation.
Thus in looking for potential etiology factors of
CRSwNP, we assessed allergy, AERD, asthma and
microbiologic status of nasal cavity for their correlation
with RAGE and HMGB1. Shim et al. (2012) showed that
HMGB1 expression was markedly higher in asthmatics
than in NC and positively correlated with eosinophilic
airway inflammation and non-specific airway hyper
responsiveness. Furthermore, they found that enhanced
RAGE expression on CD11b-CD11c(?) also significantly
decreased when HMGB1 activity was blocked. In regard to
this study, we observed significantly stronger RAGE
intensity in sinus mucosa of patients who suffered from
asthma and AERD compared to other patients with nega-
tive anamnesis but we did not find any correlation between
RAGE expression vs. allergy status.
In addition tomorphologic changes as a potential cause of
the altered tissue levels of sRAGE, some authors reported
increased colonization rate of Staphylococcus aureus in the
upper airways of CRSwNP patients as a potentially novel
contributor to the overall reduction in sRAGE in this patient
group (Van Zele et al. 2004). Van Crombruggen et al. (2012)
in ex vivo human tissue experiments showed that S. aureus
was able to release free sRAGE into the tissue culture
medium, otherwise sRAGE could be detected in the tissue-
cube pellet only as tissue-associated sRAGE. In our study,
however, the microbiological status of nasal cavity and any
specific microbe did not correlate with RAGE expression
(p[ 0.05).
The potential pathogenic role of RAGE in other
inflammatory disorders was supported by a few studies
demonstrating that anti-RAGE/HMGB1 antibodies prevent
chronic inflammation (Ostberg et al. 2010; Pisetsky et al.
2008). Application of this antibody could be effective in
terms of improvement of the therapeutic repertoire for
CRSwNP.
In conclusions, it is possible that the explanation for
CRSwNP pathogenesis might be related to RAGE over
expression with subsequent sinus mucosa hyper prolifera-
tion, recurrent NPs formation necessitating several
operations. This observation potentially opens new ways
for investigation of the RAGE function as one of the rea-
sons for inflammation related to CRSwNP.
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